Efficacy and Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with DA-EPOCH-R Regimen: A Single-Centre Experience

Abstract

Introduction:

Primary Mediastinal B-Cell Lymphoma (PMBCL) is an aggressive subtype of non-Hodgkin lymphoma (NHL). One of the current recommended first-line treatments for PMBCL is a dose-adjusted (DA)-EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) regimen. This study aimed to determine the outcome of PMBCL patients treated with DA-EPOCH-R.

Methods:

We performed a retrospective, single-centre study of patients aged 18 years and above, diagnosed with PMBCL and treated with DA-EPOCH-R between January 2013 and December 2017. A total of seven patients were included in the analysis. The primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes were complete response (CR), overall response rate, and treatment-related neutropenia.

Results:

The median progression-free survival (PFS) and overall survival (OS) were 5.5 months and 13.4 months, respectively. No patient achieved a complete response (CR). One patient underwent an autologous stem cell transplant, and one underwent consolidative radiotherapy.

Conclusion:

The outcome of this study is inferior to the previous studies, possibly due to the lack of dose escalation of the DA-EPOCH-R regimen.